NCT07105215 - A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors | Biotech Hunter

Enrollment

312

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

May 31, 2030

Conditions

Solid Tumors

Interventions

DRUG

RC278

Intravenous (IV) administration of RC278 Q3W. Patients will continue treatment until unacceptable toxicities, disease progression, or any criterion for withdrawl from the study.

Trial Locations (6)

Unknown

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

RECRUITING

The First Affiliated Hospital, Zhejiang University School Of Medicine, Hangzhou

RECRUITING

Cancer Hospital of Shandong First Medical University, Jinan

RECRUITING

Jinan Central Hospital, Jinan

RECRUITING

Shanxi Cancer Hospital, Taiyuan

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY